Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

CARL. Anniversary at the EuroELSO in Lisbon

Exactly one year ago, CARL was presented for the first time to an international audience at EuroELSO 2022 in London. Exactly 12 months later, an extremely positive balance can be drawn after EuroELSO 2023 in Lisbon. With over 350 participants, the CARL Lunch Symposium on “CARL – The next level of ECPR?” was the best-attended industry symposium of the congress. Dinis Dos Reis Miranda (Rotterdam), Eike Tigges (Hamburg) and Matthias Lubnow (Regensburg), as early users, reported on their previous in- and out-of-hospital applications and the potential of CARL as a second chance for survival in the extended rescue chain.

The CARL booth was very busy throughout the congress. The intensive cooperation with all CARL sales partners in Europe was particularly pleasing. This year, CARL Technology was not only explained by the experts of the CARL Academy, but also by the respective product specialists of the different sales organizations.

In the two training units on “ECPR Simulation – Cannulation during high quality CPR”, which were fully booked with more than twenty participants each, the role of CARL in an interdisciplinary resuscitation scenario was successfully communicated under the direction of the CARL Academy. The CARL Spotlight of the second day of the congress – Jan Bělohlávek (Prague), one of the most renowned ECPR opinion leaders worldwide, demonstrated how important and life-saving time can be saved during ECPR implementation with an extremely fast cannulation and advice from practice.

“I am very pleased to see that our footprint in Europe has increased significantly. The overwhelming participation in our events and the consistently good feedback show us that we are on the right track towards a sustainable implementation of CARL in Europe,” says Patrick Rauh, Commercial Director of Resuscitec GmbH.


< Back